Holen Sie sich die Stockscreener-App
433.61
0.33%
1.44
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt VRTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$432.17
Offen:
$434.67
24-Stunden-Volumen:
750.55K
Relative Volume:
0.50
Marktkapitalisierung:
$110.02B
Einnahmen:
$11.74B
Nettoeinkommen (Verlust:
$3.68B
KGV:
30.56
EPS:
14.1888
Netto-Cashflow:
$3.34B
1W Leistung:
+1.61%
1M Leistung:
+2.66%
6M Leistung:
-2.58%
1J Leistung:
-6.66%
1-Tages-Spanne:
$429.07
$434.67
1-Wochen-Bereich:
$423.87
$434.67
52-Wochen-Spanne:
$362.50
$519.68
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Firmenname
Vertex Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 341-6393
Adresse
50 NORTHERN AVENUE, BOSTON, MA
Vergleichen Sie VRTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-09-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Eingeleitet | Raymond James | Mkt Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-19 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-02-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Herabstufung | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-05-04 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-01-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-05-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Bestätigt | JP Morgan | Overweight |
| 2022-01-27 | Bestätigt | Morgan Stanley | Underweight |
| 2022-01-27 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Hold |
| 2022-01-27 | Bestätigt | Wolfe Research | Outperform |
| 2022-01-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-30 | Eingeleitet | Daiwa Securities | Outperform |
| 2020-11-30 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Eingeleitet | Bernstein | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-07-31 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-09-03 | Hochstufung | Goldman | Neutral → Buy |
| 2019-08-01 | Herabstufung | Needham | Buy → Hold |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | In-line |
| 2019-03-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
Is Vertex Pharmaceuticals Stock Underperforming the Nasdaq? - Barchart.com
Kidney Disease Trial Success Might Change The Case For Investing In Vertex Pharmaceuticals (VRTX) - Yahoo Finance
How analysts rate Vertex Pharmaceuticals Incorporated stock today2025 Key Highlights & Scalable Portfolio Growth Methods - BỘ NỘI VỤ
Is Vertex Pharmaceuticals Incorporated stock ready for breakoutJuly 2025 Recap & Reliable Breakout Stock Forecasts - moha.gov.vn
Is Vertex Still a Bargain After Latest Pipeline Progress and Five Year 90.6% Gain? - Yahoo Finance
Where Will Vertex Pharmaceuticals Be in 5 Years - sharewise.com
Vertex Pharmaceuticals names Wafi Alshehri as HRBP Director for KSA and the GCC - Indiatimes
What Do Analysts Think About Vertex Pharmaceuticals (VRTX)? - Finviz
Interest rate-sensitive biotech companies are bullish on the New York Stock Exchange. Hedge funds ha.. - 매일경제
Scotiabank Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Vertex Pharmaceuticals (VRTX) Leads Hedge Fund Interest in Q3 20 - GuruFocus
2 Healthcare Stocks For Beginner Investors With a 30-Year Time Horizon - Finviz
2 Healthcare Stocks For Beginner Investors With a 30-Year Time Horizon - The Motley Fool
Vertex Pharmaceuticals (VRTX) Stock Trades Up, Here Is Why - Finviz
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Is Vertex Pharmaceuticals Incorporated a good long term investmentVolatility Index Analysis & Big Returns Low Cost - earlytimes.in
Vertex Pharmaceuticals Stock: Analyst Estimates & Ratings - MSN
[Form 4] VERTEX PHARMACEUTICALS INC / MA Insider Trading Activity - Stock Titan
Shareholder Carney Lloyd Foundation Files To Sell 800 Of Vertex Pharmaceuticals Inc [VRTX] - TradingView
2 Inflation-Proof Growth Stocks That Could Outperform the Market - Finviz
Vertex Nears Historic Breakthrough: Stem Cell Therapy Poised to Transform Type 1 Diabetes Treatment - Azat TV
Vertex Pharmaceuticals Incorporated (0QZU.IL) stock price, news, quote and history - Yahoo Finance UK
How risky is Vertex Pharmaceuticals Incorporated (VX1) stock compared to peers2025 Technical Overview & Free Weekly Watchlist of Top Performers - newser.com
How Vertex Pharmaceuticals Incorporated (VX1) stock moves on employment dataGold Moves & Weekly Chart Analysis and Guides - newser.com
Insider Sell: Atkinson Edward Morrow III Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex, Crispr’s Casgevy Accused of Infringing New ToolGen Patent - Bloomberg Law News
Vertex Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors - 富途牛牛
Vertex Pharmaceuticals Inc. Stock Falls 3.3%, Underperforms Peers - 富途牛牛
VP Atkinson III Sells 2,500 ($1.1M) Of Vertex Pharmaceuticals Inc [VRTX] - TradingView
Vertex to Participate in the Citi’s 2025 Global Healthcare Conference on December 3 - Business Wire
Published on: 2025-11-19 14:57:49 - newser.com
Published on: 2025-11-19 14:24:13 - newser.com
Published on: 2025-11-19 03:57:22 - newser.com
Is Vertex Pharmaceuticals Incorporated (VX1) stock a buy on weakness - newser.com
Vertex Pharmaceuticals Incorporated’s volatility index tracking explainedJuly 2025 Setups & Accurate Trade Setup Notifications - newser.com
Will Vertex Pharmaceuticals Incorporated benefit from macro trendsTrade Volume Report & Reliable Intraday Trade Alerts - newser.com
Exit strategy if you’re trapped in Vertex Pharmaceuticals Incorporated2025 Sector Review & Risk Adjusted Buy/Sell Alerts - newser.com
Is Vertex Pharmaceuticals Incorporated stock a smart buy before Fed meetingPortfolio Gains Report & Technical Confirmation Trade Alerts - newser.com
A Look at Vertex Pharmaceuticals’s Valuation Following Promising Kidney Trial Updates and New FDA Designations - Yahoo Finance
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Stifel Maintains Hold Rating on Vertex (VRTX), Keeps $445 Price Target - MSN
1 Incredible Reason to Buy Vertex Pharmaceuticals Stock in November - sharewise.com
Finanzdaten der Vertex Pharmaceuticals Inc-Aktie (VRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.56%
1.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):